Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Lymphoid Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00003451
What this trial is testing

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Very early researchNot Yet RecruitingNCT06849401
What this trial is testing

The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia

Who this might be right for
T-ALL
Shanghai Jiao Tong University School of Medicine 9
Early research (Phase 1)Study completedNCT00278330
What this trial is testing

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Who this might be right for
Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI) 24
Early research (Phase 1)Active Not RecruitingNCT03016377
What this trial is testing

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Who this might be right for
Acute Lymphoblastic LeukemiaImmune System DiseasesImmunoproliferative Disorders
UNC Lineberger Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Ended earlyNCT04874194
What this trial is testing

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid Leukemia+4 more
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT00975975
What this trial is testing

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous Leukemia+8 more
Indiana University 17
Not applicableNot Yet RecruitingNCT07710781
What this trial is testing

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaAcute Lymphoblastic Leukemia+9 more
Ossium Health, Inc. 300
Testing effectiveness (Phase 2)UnknownNCT04271800
What this trial is testing

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Who this might be right for
LeukemiaLymphomaLeukemia, B-Cell+1 more
Chongqing Precision Biotech Co., Ltd 40
Testing effectiveness (Phase 2)Ended earlyNCT01116232
What this trial is testing

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Barbara Ann Karmanos Cancer Institute 4
Early research (Phase 1)UnknownNCT05398614
What this trial is testing

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Who this might be right for
T-ALLLymphoma, T-Cell
Hebei Senlang Biotechnology Inc., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT00274963
What this trial is testing

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 60
Testing effectiveness (Phase 2)Looking for participantsNCT06376721
What this trial is testing

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeT-lymphoblastic Lymphoma
Beijing Tongren Hospital 43
Testing effectiveness (Phase 2)UnknownNCT00923663
What this trial is testing

Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Who this might be right for
MALT Lymphoma
Medical University of Vienna 16
Testing effectiveness (Phase 2)Looking for participantsNCT04684147
What this trial is testing

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT01515176
What this trial is testing

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+1 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Study completedNCT00049413
What this trial is testing

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT02005289
What this trial is testing

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Who this might be right for
Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic Leukemia+9 more
Ohio State University Comprehensive Cancer Center 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Next Page